Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,295
datasets available to search
ShareScore release 0.9.0
Dataset results
1,295 results for “Exosome”
Plasma exosomes from individuals with type 2 diabetes drive breast cancer aggression in patient-derived organoids
GEO Series GSE302054. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Exosomal miR-92a-3p as a diagnostic biomarker for adenomyosis and its pathological mechanism
GEO Series GSE262302. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing.
Exosome release is regulated by mTORC1 via a Rab27A-dependent mechanism
GEO Series GSE114235. Homo sapiens. 2 samples. Type: Non-coding RNA profiling by high throughput sequencing.
miRNA profiles of plasma and tumor-derived exosomes of cardiac myxoma-related ischemic stroke
GEO Series GSE272079. Homo sapiens. 20 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia
<p><strong>Supplementary Materials</strong></p> <p>Figure S1. PI resistance is reversible in MLL cells.</p> <p>Figure S2. PI-treated cell-derived exosomes induce cell cycle arrest and PI resistance in SEM cells.</p> <p>Figure S3. Unsupervised hierarchical clustering heatmap of differentially expressed proteins in RS4;11-Nexo- or RS4;11-Rexo-treated RS4;11 cells.</p> <p>Figure S4. Integrated network nodes and edges related to “upstream” exosomal proteins.</p> <p>Figure S5. Integrated network nodes and edges related to “downstream” genes in the transcriptome profile of recipient cells.</p> <p>Figure S6. Potential therapeutic targets related to exosomal regulatory proteins.</p> <p>Figure S7. TieDIE integration network nodes and edges related to the cell cycle pathway.</p> <p>Figure S8. TieDIE integration network nodes and edges related to the stemness pathway.</p> <p>Figure S9. The original western blot images in this manuscript.</p> <p>Table S1. Differentially expressed proteins in exosomes.</p> <p>Table S2. Nodes of the TieDIE integrated network.</p> <p>Table S3. The exosomal regulatory proteins and the corresponding drugs or compounds.</p>
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD- 1 agents
<p><strong>ABSTRACT</strong></p> <p><strong>Background</strong></p> <p>CD73 is an ectonucleotidase producing the immunosuppressor mediator adenosine. Elevated levels of circulating CD73 in patients with cancer have been associated with disease progression and poor response to immunotherapy. Immunosuppressive pathways associated with exosomes can affect T-cell function and the therapeutic efficacy of anti-programmed cell-death<br> protein 1 (anti-PD-1) therapy. Here, we conducted a retrospective pilot study to evaluate levels of exosomal CD73 before and<br> early during treatment with anti-PD-1 agents in patients with melanoma and its potential contribution to affect T-cell functions and to influence the clinical outcomes of anti-PD-1 monotherapy.</p> <p><strong>Methods</strong></p> <p>Exosomes were isolated by mini size exclusion chromatography from serum of patients with melanoma (n=41) receiving nivolumab or pembrolizumab monotherapy. Expression of CD73 and programmed death-ligand 1 (PD-L1) were evaluated on exosomes enriched<br> for CD63 by on-bead flow cytometry. The CD73 AMPase activity was evaluated by mass spectrometry, also in the presence of selective inhibitors of CD73. Interferon (IFN)-γ production and granzyme B expression were measured in CD3/28 activated T cells incubated with exosomes in presence of the CD73 substrate AMP. Levels of CD73 and PD-L1 on exosomes were correlated with therapy response. Exosomes isolated from healthy subjects were used as control.</p> <p><strong>Results</strong></p> <p>Isolated exosomes carried CD73 on their surface, which is enzymatically active in producing adenosine. Incubation of exosomes with CD3/28 activated T cells in the presence of AMP resulted in a significant reduction of IFN-γ release, which was reversed by the<br> CD73 inhibitor APCP or by the selective A2A adenosine receptor antagonist ZM241385. Expression levels of exosomal CD73 from serum of patients with melanoma were not significantly different from those in healthy subjects. Early on-treatment, expression levels of both CD73 and PD-L1 on exosomes isolated from patients receiving pembrolizumab or nivolumab monotherapy were<br> significantly increased compared with baseline. Early during therapy exosomal PD-L1 increased in responders, while exosomal CD73 resulted significantly increased in non-responders.</p> <p><strong>Conclusions </strong></p> <p>CD73 expressed on exosomes from serum of patients with melanoma produces adenosine and contributes to suppress T-cell functions. Early on-treatment, elevated expression levels of exosomal CD73 might affect the response to anti-PD-1 agents in patients with melanoma who failed to respond to therapy.</p> <p> </p> <p><strong>Funding </strong></p> <p>This work was supported by FARB 2020 University of Salerno (SM), P.O.R. Campania FESR 2007–2013 - O.O. 2.1 - OCKEY (SM), POR Campania, FESR 2014/2020 (Asse 1—Obiettivo specifico 1.2—Azione 1.2) Project: Campania OncoTerapie CUP: B61G18000470007 and Italian Ministry of Health (IT-MOH) through 'Ricerca Corrente' M2/M (PAA).</p>
An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer
ClinicalTrials.gov study NCT05559177. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies
ClinicalTrials.gov study NCT04288141. IPD Sharing: NO. Countries: 1. Publications: 0.
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
ClinicalTrials.gov study NCT04948437. IPD Sharing: NO. Countries: 1. Publications: 0.
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
ClinicalTrials.gov study NCT03032913. IPD Sharing: NO. Countries: 1. Publications: 0.
The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer
ClinicalTrials.gov study NCT05579353. IPD Sharing: YES. Countries: 1. Publications: 0.
Combined Photo-Biomodulation At Acupuncture Points, Autologous PRP, and Umbilical Cord-Derived Exosome Therapy in Autism Spectrum Disorder
ClinicalTrials.gov study NCT06600529. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Exosome microRNAs as Potential Biomarkers of Metabolic Bone Disease of Prematurity
ClinicalTrials.gov study NCT06368154. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation
ClinicalTrials.gov study NCT03478410. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus
ClinicalTrials.gov study NCT05387278. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma
ClinicalTrials.gov study NCT05101655. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis
ClinicalTrials.gov study NCT07177742. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection
ClinicalTrials.gov study NCT04544215. IPD Sharing: YES. Countries: 1. Publications: 0.
Major Activation Of NCC in Graft Urinary Exosomes
ClinicalTrials.gov study NCT03503461. IPD Sharing: NO. Countries: 2. Publications: 0.
Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes
ClinicalTrials.gov study NCT06955767. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.